SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia
Olga Frolova, Juliana Benito, Chris Brooks, Rui Yu Wang, Borys Korchin, Eric K. Rowinsky, Jorge Cortes, Hagop Kantarjian, Michael Andreeff, Arthur E. Frankel, Marina Konopleva
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia'. Together they form a unique fingerprint.